<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02329457</url>
  </required_header>
  <id_info>
    <org_study_id>HKU 11-174</org_study_id>
    <nct_id>NCT02329457</nct_id>
  </id_info>
  <brief_title>VZV Vaccine for Hematopoietic Stem Cell Transplantation</brief_title>
  <acronym>VZIDST</acronym>
  <official_title>Efficacy and Safety of a Novel Intradermal Live-attenuated Varicella Zoster Vaccine in Hematopoietic Stem Cell Transplantation Donors: a Randomized Double Blind Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hematopoietic stem cell transplantation (HSCT) is well-established therapy for patients with
      malignant hematological diseases. Varicella zoster virus (VZV) reactivation, clinically
      manifested as herpes zoster (HZ), is a major complication that affects up to 50% of patients.
      Most patients will require hospitalization. Despite treatment with high dose acyclovir,
      patients may develop severe complications including the disabling postherpetic neuralgia,
      corneal ulceration, viral dissemination and secondary bacterial infection. The median onset
      of infection is the fifth month following transplantation, with 91% of cases occurring within
      the first year. Direct vaccination of transplants recipients with subcutaneous
      live-attenuated VZVv before transplantation and up to one year after transplantation is
      contraindicated. A small prospective non-randomized study has demonstrated that subcutaneous
      vaccination for donors before HSCT may offer some protection against VZV reactivation in the
      recipients. Recently, dose-sparing influenza vaccine delivered via a novel intradermal
      microneedle has been shown to elicit a good immunogenic response in both healthy and elderly
      subjects. We sought to assess the efficacy and safety of the novel intradermal
      live-attenuated VZVv in sibling donors undergoing HSCT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hematopoietic stem cell transplantation (HSCT) is well-established therapy for patients with
      malignant hematological diseases. Varicella zoster virus (VZV) reactivation, clinically
      manifested as herpes zoster (HZ), is a major complication that affects up to 50% of patients.
      Most patients will require hospitalization. Despite treatment with high dose acyclovir,
      patients may develop severe complications including the disabling postherpetic neuralgia,
      corneal ulceration, viral dissemination and secondary bacterial infection. The median onset
      of infection is the fifth month following transplantation, with 91% of cases occurring within
      the first year. Direct vaccination of transplants recipients with subcutaneous
      live-attenuated VZVv before transplantation and up to one year after transplantation is
      contraindicated. A small prospective non-randomized study has demonstrated that subcutaneous
      vaccination for donors before HSCT may offer some protection against VZV reactivation in the
      recipients. Recently, dose-sparing influenza vaccine delivered via a novel intradermal
      microneedle has been shown to elicit a good immunogenic response in both healthy and elderly
      subjects. We sought to assess the efficacy and safety of the novel intradermal
      live-attenuated VZVv in sibling donors undergoing HSCT.

      We plan to enroll 160 pairs of adult donors and patients who undergo allogeneic HLA matched
      sibling HSCT in this prospective randomized double-blind placebo-controlled trial over a
      period of 3 years. Enrolled donors and patients will be randomized into 4 groups: Group 1:
      intradermal reduced dose live-attenuated VZVv; Group 2: subcutaneous full dose
      live-attenuated VZVv; Group 3: intradermal 0.9% normal saline as control; Group 4:
      subcutaneous 0.9% normal saline as the second control; Group 5: intradermal reduced dose
      live-attenuated VZVv with topical imiquimod pretreatment.

      All vaccines will be given to the donors at 28 days. All intradermal vaccines will be given
      via a microneedle syringe. Both the investigators and participants will be blinded to the
      randomization process. The primary end points are the safety and immunological response in
      the donors. The secondary end point is the occurrence of HZ in the patients within 12 months
      of transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunological response in donors</measure>
    <time_frame>30 days post transplantation</time_frame>
    <description>Anti-VZV antibody</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunological response in donors</measure>
    <time_frame>90, 180 and 360 days post transplantation</time_frame>
    <description>Anti-VZV antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological response in donors</measure>
    <time_frame>30 and 180 days post transplantation</time_frame>
    <description>Cellular immunity assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Herpes zoster reactivation</measure>
    <time_frame>12 months post transplantation</time_frame>
    <description>Herpes zoster reactivation in recipients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reaction</measure>
    <time_frame>21 days after vaccination</time_frame>
    <description>Adverse reaction in donors after vaccination</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Varicella Zoster Infection</condition>
  <arm_group>
    <arm_group_label>ID varicella zoster vaccine (VZVv) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intradermal 0.2 mL Zostavax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC VZVv group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subcutaneous 0.65 mL Zostavax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ID NS Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intradermal 0.2 mL normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC NS Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subcutaneous 0.65 mL normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ID VZVv with imiquimod group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intradermal 0.2mL Zostavax with imiquimod pretreatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Zostavax</intervention_name>
    <description>varicella zoster vaccine</description>
    <arm_group_label>ID varicella zoster vaccine (VZVv) group</arm_group_label>
    <arm_group_label>SC VZVv group</arm_group_label>
    <arm_group_label>ID VZVv with imiquimod group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>normal saline placebo vaccine</description>
    <arm_group_label>ID NS Group</arm_group_label>
    <arm_group_label>SC NS Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing allogeneic hemopoietic stem cell transplant

          -  HLA identical sibling donors

          -  participants willing to provide written informed consents

        Exclusion Criteria:

          -  history of zoster in the 12 months prior to transplantation

          -  exposure to VZV within 4 weeks of transplantation

          -  neomycin sensitivity

          -  sensitivity to any components of the zoster vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan FN Hung, MD FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ivan FN Hung, MD FRCP</last_name>
    <phone>852-22554049</phone>
    <email>ivanfn@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ivan Hung</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan FN Hung, MD FRCP</last_name>
      <phone>852 22554049</phone>
      <email>ivanfn@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Kelvin To, MD FRCPath</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>KY Yuen, MD FRCPath</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <results_reference>
    <citation>Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K, Arvin AM. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med. 2002 Jul 4;347(1):26-34.</citation>
    <PMID>12097537</PMID>
  </results_reference>
  <results_reference>
    <citation>Leung AY, Chow HC, Kwok JS, Lui CK, Cheng VC, Yuen KY, Lie AK, Liang R. Safety of vaccinating sibling donors with live-attenuated varicella zoster vaccine before hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun;39(11):661-5. Epub 2007 Apr 9.</citation>
    <PMID>17417658</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2014</study_first_submitted>
  <study_first_submitted_qc>December 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2014</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>double-blind, randomized, intradermal, VZVv, HSCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

